SCHEMBL23040449

SCHEMBL23040449

CCCCOC(=O)N1CCCC(c2ccc(N)cc2)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.49
CYP1A2 P05177 2/20 0.49
CYP3A4 P08684 2/20 0.49
CYP2C9 P11712 1/20 0.49
TSHR P16473 1/20 0.49
CYP2C19 P33261 1/20 0.49
PDE4D Q08499 1/20 0.49
PDE4B Q07343 2/20 0.47
PRMT5 O14744 2/20 0.45
WDR77 Q9BQA1 2/20 0.45
ALDH1A1 P00352 3/20 0.44
NPC1 O15118 1/20 0.44
MAPT P10636 1/20 0.44
RAB9A P51151 1/20 0.44
HPGD P15428 2/20 0.42
HIF1A Q16665 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
POLB P06746 1/20 0.42
PROKR1 Q8TCW9 4/20 0.42
HSD11B1 P28845 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2025839 0.94 PDE4B (0.53) LMNACYP1A2CYP3A4CYP2C9TSHR
SCHEMBL31455322 0.89 LMNA (0.51) LMNACYP1A2CYP3A4CYP2C9TSHR
SCHEMBL30376364 0.86 LMNA (0.49) LMNACYP1A2CYP3A4CYP2C9TSHR
SCHEMBL2047643 0.82 LMNA (0.45) LMNACYP1A2CYP3A4CYP2C9TSHR
SCHEMBL4709679 0.81 PRMT5 (0.64) LMNACYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL22659030 0.80 PDE4B (0.53) LMNAPDE4DPDE4BPRMT5WDR77
SCHEMBL15531501 0.80 LMNA (0.50) LMNACYP1A2CYP3A4CYP2C9TSHR
SCHEMBL31421713 0.80 LMNA (0.47) LMNACYP1A2CYP3A4CYP2C9TSHR
SCHEMBL2023788 0.79 LMNA (0.49) LMNACYP1A2CYP3A4CYP2C9TSHR
SCHEMBL1988650 0.78 PDE4B (0.52) PDE4BPRMT5ALDH1A1NPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11697636-B2 Substituted benzamides HOFFMANN-LA ROCHE INC. (US) 2023-07-11 US disclosed
US-20210061760-A1 SUBSTITUTED BENZAMIDES HOFFMANN LA ROCHE (US) 2021-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210061760-A1 SUBSTITUTED BENZAMIDES TAAR1, TAAR5, NPY1R LMNA 3001/4885CYP1A2 164/4885CYP3A4 510/4885
US-11697636-B2 Substituted benzamides TAAR1, TAAR5, NPY1R LMNA 3001/4885CYP1A2 164/4885CYP3A4 510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.